A recombinant vector, host cell and process for production of human serum albumin. The disclosure represents an advancement in the field of genetic engineering and discloses a modified pPIC9 vector comprising a nucleic acid (SEQ ID NO:5) encoding human serum albumin for achieving optimum expression of human serum albumin in Pichia pastoris host cell. The disclosure also discloses a modified process for producing recombinant human serum albumin.

The present disclosure provides culture or fermentation media including a biomass or derivative thereof of a hemoprotein-producing C.sub.1 metabolizing non-photosynthetic bacterium, methods of culturing cells or tissue with the culture or fermentation medium, and products produced by the culturing methods including food products, food ingredients, phytoprotective bacterial cell products, and other products of interest such as vitamins, fatty acids, amino acid, carotenoids, etc.

Compositions and methods are provided for controlling Fusarium fungal infections in plants. In particular, the subject invention relates to treatments for plant pathogenic fungal infections using microbes and/or their growth by-products. In a specific embodiment, the subject invention can be used to treat and/or prevent infection from a strain of Fusarium oxysporum that causes Fusarium Wilt and/or Panama Disease in Musa plants, although control of other Fusarium infections in other plants and/or agricultural products is also envisioned.

The present disclosure provides a recombinant collagen and a recombinant collagen sponge material. The recombinant collagen comprises: (a) a protein composed of the amino acid sequence represented by SEQ ID NO: 2; and/or (b) a protein which has the same function as (a) and is derived from (a) by substitution, deletion and/or addition of one or more amino acids in SEQ ID NO:2. The recombinant collagen sponge material is obtained by sequential physical cross-linking and chemical cross-linking of the recombinant collagen. The recombinant collagen sponge material according to the present disclosure is capable of hemostasis, wound surface repair, moisture absorption and platelet aggregation, and has high moisture absorption, a significant hemostatic effect and good biocompatibility, assuming great clinical significance in the field of surgery.

The present disclosure provides recombinant Pichia pastoris, a construction method thereof, and use thereof in the efficient preparation of 15α-D-ethylgonendione, and belongs to the technical field of fermentation engineering. In the present disclosure, with Pichia pastoris as a host, 15α-steroid hydroxylase and glucose-6-phosphate dehydrogenase (G6PD) are simultaneously induced in a manner of intracellular enzyme production for the first time, and the Pichia pastoris whole-cell induction and catalysis mode is used to achieve the conversion of D-ethylgonendione with high substrate loading and high conversion rate.

The current inventive technology includes novel systems, methods and compositions for the in vivo production, modification and isolation of terpene compounds from Cannabis or other plants. In particular, the invention provides systems and methods for high level in vivo biosynthesis of water-soluble terpene compounds. In one preferred embodiment, the present invention generally relates to the conversion of Cannabis sativa or hemp derived terpenes into water-soluble terpene compounds, such as terpene glycosides, glycosylated-xylosylated terpenes, and an acetylated glycoside terpenes. In one preferred aspect, the invention may include system for producing water-soluble terpene compounds in yeast and tobacco cell suspension cultures, as well as an in planta system using transgenic Cannabis or hemp plants.

The present invention relates to granulysin, method of obtaining same, and uses, specifically to the granulysin polypeptide for the use thereof as a medicinal product via the systemic route and to a chimeric molecule comprising a recombinant antibody targeting a tumor antigen and the granulysin polypeptide.

The present disclosure relates, according to some embodiments, to compositions, methods, and/or kits for producing vaccinia capping enzyme. For example, active, heterodimers of vaccinia capping enzyme may be produced as fusions comprising D1 and D12 subunits. Vaccinia capping enzyme fusion proteins may further comprise a linker.

Described herein is a meat substitute or food ingredient comprising an animal myoglobin protein, gene construct comprising a nucleic acid encoding said protein, a host cell comprising said gene construct and a method for producing said myoglobin or said meat substitute.

Provided herein are methods for identifying and isolating polynucleotides coding for polypeptides having D-allulose 3-epimerase activity from a wide variety of microorganisms. Also provided are nucleic acid constructs, vectors and recombinant host cells comprising the polynucleotides coding for D-allulose 3-epimerase activity as well as methods for producing allulose from fructose using said recombinant host cells having D-allulose 3-epimerase activity or the D-allulose 3-epimerase enzyme of said recombinant host cells having D-allulose 3-epimerase activity.